Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388130 | 1.00 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL122314 | 1.00 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL22718395 | 0.98 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| Alcohol SCHEMBL10979775 | 0.96 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL28250077 | 0.94 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| Malonic Acid Diethyl Ester SCHEMBL28250078 | 0.94 | GAA (0.62) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL21055891 | 0.92 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL12189521 | 0.89 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1233485 | 0.88 | MGAM (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL22303945 | 0.87 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114292412-B | Covalent organic framework material based on quinoline ring connection and preparation method thereof | 北京理工大学 | 2022-09-20 | — | — | CN | claimed |
| CN-114292412-A | Covalent organic framework material based on quinoline ring connection and preparation method thereof | 北京理工大学 | 2022-04-08 | — | — | CN | claimed |
| US-20060128789-A1 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | claimed |
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | UNIV CALIFORNIA (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4452416-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118786129-A | Covalent binding inhibitors of G12S, G D and/or G12E mutants of K-RAS GTPases | 加利福尼亚大学董事会 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023131362-A1 | PHENYLPROPANOID DERIVATIVES | USTAV EXPERIMENTALNI BOTANIKY AV ČR, V. V. I. (CZ) | 2023-07-13 | — | — | WO | disclosed |
| CN-116396285-A | Preparation and application of deuterated tetrahydrofuran compound | 上海华汇拓医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023122662-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Pheon Therapeutics Ltd. (GB) | 2022-03-31 | — | — | US | disclosed |
| US-20040249175-A1 | Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol | Janssen Sciences Ireland Unlimited Company (IE) | 2004-12-09 | — | — | US | disclosed |
| CN-1553915-A | Process for preparing hexahydro-furo [2, 3-b ] furan-3-ol | ̩���ؿ�ҩƷ����˾ | 2004-12-08 | — | — | CN | disclosed |
| EP-1448567-A1 | METHOD FOR THE PREPARATION OF HEXAHYDRO-FURO 2,3-B]FURAN-3-OL | Tibotec Pharmaceuticals Ltd. (IE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003022853-A1 | METHOD FOR THE PREPARATION OF HEXAHYDRO-FURO[2,3-B]FURAN-3-OL | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-03-20 | — | — | WO | disclosed |
| CN-1101368-C | Process for prepn. of butane triols | AVECIA LTD (GB) | 2003-02-12 | — | — | CN | disclosed |
| US-6376683-B1 | ESTERIFICATION OF MALIC ACID WITH ALCOHOL; REDUCTION; CYCLIZATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-04-23 | — | — | US | disclosed |
| CN-1234016-A | Process for prepn. of butane triols | ZENECA LTD (GB) | 1999-11-03 | — | — | CN | disclosed |
| US-5342981-A | Substantially isomerically pure hexane or hexene compounds | ABBOTT LABORATORIES (US) | 1994-08-30 | — | — | US | disclosed |
| US-5229518-A | Isomerically pure 2-piperidone compounds | ABBOTT LABORATORIES (US) | 1993-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | MGAM 2966/4885GAA 361/4885SI 1325/4885 |
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | CCNA1, GNA15, RPS26 | MGAM 4497/4885GAA 3482/4885SI 4565/4885 |
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | KRAS, HRAS, NRAS | MGAM 2145/4885GAA 2872/4885SI 2273/4885 |
| US-20040249175-A1 | Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol | HAAO, BBOX1, FBP1 | MGAM 595/4885GAA 1530/4885SI 871/4885 |
| US-20060128789-A1 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | PNISR, PNMT, GRHPR | MGAM 541/4885GAA 2655/4885SI 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.